

Financia	results b	v company
----------	-----------	-----------

_		tandalone Unaudi					
	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for current period ended	Previous year ended
		(30/09/2017)	(30/06/2017)	(30/09/2016)	(30/09/2017)	(30/09/2016)	(31/03/2017)
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
ı	Revenue from Operation						
	Other Operating Revenue	5.75	100.83	38.80	106.58	184.93	517.23
_	Other income	2,94	2.01	1.15	4.95	2.43	2.68
	Total Revenue (I + II)	8.69	102.84	39,95	111.53	187,36	519.91
IV	Expenses	//12 (2)	25.20	10.06	11.66	40.01	0.6.05
	(a) Cost of materials consumed	(13.62)	25.28	12.96	11.66	43.31	86.07
	(b) Purchase of stock-in-trade	0,00	0.00	0.00	0.00	0,00	0.00
	© Changes in inventories of finished goods, work-in-progress and stock-in-trade	(16.95)	0.00	4,71	(16.95)	3,62	12.03
_	(d) Employee benefits expense	31.42	25.47	25.84	56.89	49.51	118.21
-	(e) Finance Cost	0.00	0.19	0.00	0.19	0.00	0.00
-	(f) Depreciation and amortisation expense	7.50	12.50	11.20	20.00	24.35	46.59
-	(g) Other expenses	(0.61)	29.17	20.06	28.56	30.16	152.09
_	(g) Other expenses	(0.01)	27.17	20.00	26.30	30.10	132.09
_	Total expenses	7.74	92.61	74.77	100.35	150.95	414.99
V	Profit / (Loss)before exceptional and extraordinary items and tax (III - IV)	0.95	10.23	(34.82)	11.18	36.41	104.59
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
	Profit / (Loss) before extraordinary items and tax (V - VI)	0.95	10.23	(34.82)	11.18	36.41	104.59
III	Extraordinary items	0.00	0.00	0.00	0.00	0.00	0,00
IX	Profit before tax (VII- VIII)	0.95	10.23	(34.82)	11.18	36.41	104.59
X	Tax expense - Provision for taxation	0.29	3.07	0.00	3.35	11.50	38.71
	Net Profit / (Loss) or the period from continuing operations (VII-VIII)	0.66	7.16	(34.82)	7.83	24.91	65.88
XII	Profit/(loss) from discontinuing operations	0.66	7,16	(34.82)	7.83	24.91	65.88
Ш	Tax expense of discontinuing operations	0.66	7,16	(34.82)	7.83	24.91	65.88
IV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.66	7.16	(34.82)	7,83	24.91	65.88

For Shukra Pharmaceuticals Limited

Director/Authorised Signatory

CIN: L24231GJ1993PLC019079



0.66	7.16	(34.82)	7.83	24.91	65.88
142.55	156.57	156.57	156.57	156.57	156.57
			0.05	0.16	0.42
0.00	0.05	(0.22)	0.05	0.16	0.42
	156.57 0.00	156.57 156.57 0.00 0.05	156.57 156.57 156.57 0.00 0.05 (0.22)	156.57 156.57 156.57 156.57 0.00 0.05 (0.22) 0.05	0.66 7.16 (34.82) 7.65 156.57 156.57 156.57 156.57 0.00 0.05 (0.22) 0.05 0.16

- 1. The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 14th November, 2017
- 2. The Company has only single Reportable Business Segment in terms of requirements of Accounting Standard
- 3. During the quarter ended 30th September 2017, Nil complaints was received and attended.
- Previous quarter's figures have been re-grouped / re-arranged wherever necessary.
- 5. The Company has adopted Indian Accounting Standarads ("IND AS") from April 1, 2017 and accordingly these financial have been prepared in accordance with the recognition and measurements principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relavent rules issued thereunder and other accounting principles generally accepted in India. Financial Results for the previous period have been prepared in accordance with recognition and measurements pinciples of Ind AS 34.

Place: Ahmedabad Date: 14/11/2017

By Order of the Board of Directors

For, Shukra Pharmaceuticals Limited

DIN: 0703248

Chandresh Pate Director



## SHUKRA PHARMACEUTICALS LTD.

SHUKRA PHARMACEUTICALS LIMITED

STATEMENT OF ASSETS AND LIABILITIES	STANDALONE			
	As at current	As at current		
	period ended 30-09-201			
	(Unaudited)	(Audited)		
A ASSETS				
1 NON CURRENT ASSETS				
Property, Plant & Equipments	1193.16	1009.2		
Capital work in Progress	188.60			
Financial Assets				
Non Current Investments	4.43	4.4		
Loans	129.78	0.00		
Deferred Tax Assets (Net)	0.00	0.00		
Other Non Current Assets	0.00	0.00		
	1515.97	1185.80		
2 Current Assets	-	1103.00		
Inventories	66.91	31.62		
Financial Assets	00.51	31.02		
Trade Receivables	136.58	247.43		
Cash and Cash Equivalents	16.07	52.30		
Bank Balance	16.07	52.30		
Loans	351.10	272.00		
Current Tax Assets (Net)	331.10	372.08		
Other Current Assets	6.00	4.50		
ovier surrent rissees	6.90 577.56	4.53		
Total Assets	2093.53	707.96 <b>1893.7</b> 6		
EQUITY AND LIABILITIES				
1 EQUITY				
Share Capital	156.57	156.57		
Other Equity	1308.89	1301.06		
	1465.46	1457.63		
2 Liabilities	2.100.110	1457.03		
A - Non Current Liabilities				
Borrowings	209.81	3.60		
Other Financial Liabilities	0.00	0.00		
Provisions	260.84			
. 70 11310113	470.65	260.49		
B - Current Liabilities	470.03	264.09		
Borrowings	0.00			
Trade Payables	0.00	0.00		
Other Financial Liabilities	89.19	113.65		
Other Current Liabilities	0.00	0.00		
	20.90	0.00		
Provisions	47.33	58.39		
Tabel a suite and the transfer	157.42	172.04		
Total equity and liabilities	2093.53 rmaceuticals Limited	1893.76		

Director/Authorised Signatory

CIN: L24231GJ1993PLC019079